Halbert Hargrove Global Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$320 Buy
+1
New +$302 ﹤0.01% 592
2025
Q4
Sell
-23
Closed -$10.5K 383
2025
Q3
$10.5K Buy
+23
New +$9.37K ﹤0.01% 329
2025
Q2
Sell
-1
Closed -$271 328
2025
Q1
$271 Buy
+1
New +$257 ﹤0.01% 565

Other funds holding ALNY

Halbert Hargrove Global Advisors's ALNY Position: Q2 2026 in Review

Halbert Hargrove Global Advisors opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 1 share worth $320. The stake represents ﹤0.01% of the portfolio and ranks #592 among its holdings. This is a return to the name: Halbert Hargrove Global Advisors previously reported a position in ALNY as recently as Q3 2025.

Halbert Hargrove Global Advisors first reported a position in ALNY in Q1 2025 and has held it in 3 quarters since. The position peaked at $10.5K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Halbert Hargrove Global Advisors held 1 share of Alnylam Pharmaceuticals worth $320 as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Halbert Hargrove Global Advisors position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Halbert Hargrove Global Advisors's portfolio in Q2 2026, its #592 holding.
  • Halbert Hargrove Global Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Halbert Hargrove Global Advisors's Alnylam Pharmaceuticals position peaked at $10.5K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Halbert Hargrove Global Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.